Pfizer's Dividend Safety Faces Challenges Amid High Payout Ratio
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 09 2026
0mins
Should l Buy PFE?
Source: Fool
- Payout Ratio Exceeds 100%: Pfizer's payout ratio has surpassed 100% again, indicating potential risks for its quarterly dividend of $0.43, especially as the company reports negative earnings per share.
- Profitability Impacted: In its Q4 2025 report, Pfizer showed an EPS of negative $0.29 primarily due to $4.4 billion in impairment charges, although its full-year EPS of $1.36 reflects a decline from the previous year.
- Cash Flow Pressure: With free cash flow at $9.1 billion and dividend payments nearing $9.8 billion, Pfizer faces financial strain in maintaining its dividend, which could hinder future growth investments.
- Market Uncertainty: While Pfizer's financials appear better due to non-cash impairment charges, the uncertainty surrounding its future business performance suggests that risk-averse investors may want to explore safer income investments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 26.300
Low
24.00
Averages
28.56
High
35.00
Current: 26.300
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer Set to Report Earnings with Flat Revenue Expectations
- Earnings Preview: Pfizer is set to report earnings before the bell on Tuesday, with market expectations for flat revenue year-over-year, indicating a potential recovery from the 7.8% decline recorded in the same quarter last year.
- Revenue Performance: Last quarter, Pfizer reported revenues of $17.56 billion, down 1.2% year-over-year, which, while beating analyst expectations, showed a significant miss on organic revenue estimates, highlighting ongoing challenges for the company.
- Market Sentiment: Over the past month, Pfizer's stock has declined by 5.2%, contrasting sharply with peers like Eli Lilly and Merck, which reported revenue growth of 55.5% and 4.9%, respectively, indicating Pfizer's competitive disadvantages.
- Analyst Expectations: With an average analyst price target of $29.00 against a current share price of $26.38, there is a cautious outlook on Pfizer's future performance, especially as most analysts have revised their revenue estimates downward.
See More
NASDAQ 100 Pre-Market Indicator Rises Significantly
- Market Indicator Surge: The NASDAQ 100 Pre-Market Indicator rises by 205.3 points to 27,857.12, indicating a positive shift in market sentiment that may attract more investor interest in tech stocks.
- Active Stock Performance: GraniteShares 2x Long COIN Daily ETF (CONL) increases by 0.7 to $9.72 with a trading volume of 5,185,460 shares, representing a 93.63% rise from its 52-week low, reflecting sustained investor interest in cryptocurrencies.
- Intel Earnings Forecast Revisions: Intel Corporation (INTC) sees its stock price rise by 3.73 to $99.51 with 4,203,982 shares traded, as it has had 10 upward revisions in earnings forecasts over the past four weeks, showcasing market confidence in its future financial performance.
- Circle Internet Earnings Report Preview: Circle Internet Group, Inc. (CRCL) shares rise by 5.55 to $125.08 with a trading volume of 2,278,329 shares, scheduled to report earnings on May 11, 2026, with a consensus EPS forecast indicating a staggering 99,900% increase, highlighting strong growth potential.
See More
PayPal and Anheuser-Busch Beat Earnings Expectations
- PayPal Earnings Surprise: PayPal reported first-quarter earnings of $1.34 per share, exceeding analyst expectations of $1.27, with revenues of $8.35 billion surpassing the $8.05 billion forecast, indicating strong performance in the payments sector that could drive stock price increases.
- Anheuser-Busch Strong Growth: Anheuser-Busch reported earnings of $0.97 per share, beating the expected $0.89, with revenues of $15.27 billion significantly above the $14.87 billion forecast, demonstrating sustained competitiveness in the beer market that may attract more investor interest.
- Pfizer Exceeds Expectations: Pfizer's first-quarter earnings came in at $0.75 per share, above the $0.72 expected, with revenues of $14.45 billion, reflecting robust growth in the pharmaceutical sector that could enhance market confidence in its future products.
- Pinterest Optimistic Revenue Guidance: Pinterest's second-quarter revenue guidance of $1.13 billion to $1.15 billion exceeded the $1.11 billion expected, with first-quarter adjusted earnings of $0.27 per share and revenues of $1.01 billion, showcasing strong growth potential in the social media space that is likely to improve market perceptions of its long-term value.
See More
Pfizer Q1 Earnings Exceed Expectations
- Strong Performance: Pfizer reported adjusted earnings per share of 75 cents for Q1, surpassing the expected 72 cents, with revenue of $14.45 billion reflecting a 5% year-over-year increase, demonstrating robust market performance driven by both new and established products.
- Growth in New Products: The company saw a 22% operational growth in recently launched and acquired products, with the targeted cancer drug Padcev generating $591 million in revenue, a 39% increase from the previous year, exceeding analyst expectations of $542.3 million, indicating a strong return on investment in innovative therapies.
- Decline in Vaccine Sales: Despite the Covid vaccine and Paxlovid generating only $232 million and $186 million in sales, down 59% and 62% year-over-year respectively, Pfizer offset this impact with strong performance from established drugs like Eliquis, which generated $2.17 billion, a 13% increase.
- Stable Long-term Outlook: Pfizer reaffirmed its 2026 outlook, expecting adjusted earnings per share between $2.80 and $3.00 and revenue between $59.5 billion and $62.5 billion, reflecting confidence in navigating challenges from declining Covid product sales and increased market competition.
See More
Pfizer Reports Strong Q1 Earnings, Reaffirms 2026 Outlook
- Earnings Beat: Pfizer's adjusted earnings per share for Q1 reached 75 cents, exceeding the expected 72 cents, reflecting strong performance in newly launched and acquired products, which bolsters investor confidence.
- Revenue Growth: The company reported Q1 revenue of $14.45 billion, surpassing Wall Street's expectation of $13.79 billion, indicating significant growth in its new product offerings and acquisitions, further solidifying its market position.
- Strategic Acquisition: Pfizer's recent $10 billion acquisition of obesity biotech Metsera aims to diversify its product line to offset declining COVID product sales, demonstrating the company's strategic focus on future growth.
- R&D Focus: Pfizer is prioritizing several key data releases this year, including late-stage trial results for an experimental targeted drug in lung cancer, which is expected to drive new growth opportunities for its product pipeline.
See More
BioNTech to Close Sites Affecting 1,860 Jobs and Buy Back $1 Billion in Shares
- Job Cuts and Site Closures: BioNTech announced the closure of multiple sites in Idar-Oberstein, Marburg, and Tuebingen in Germany, as well as in Singapore, affecting up to 1,860 jobs, reflecting a strategic shift following the transfer of COVID-19 vaccine production to partner Pfizer.
- Executive Departures Impact: The departure of the two co-founders and key executives by year-end to focus on new treatments may impact the company's innovation capacity and market competitiveness, particularly in the vaccine sector.
- Cost-Cutting Initiatives: BioNTech plans to implement gradual cost reductions, potentially achieving annual savings of about €500 million by 2029, aimed at improving financial health amid reported net losses.
- Share Buyback Program: The company announced a share buyback of up to $1 billion over the next 12 months to bolster shareholder confidence and enhance stock prices, despite reporting a net loss of €532 million in the first quarter, indicating current financial pressures.
See More
Pfizer Set to Report Earnings with Flat Revenue Expectations
- Earnings Preview: Pfizer is set to report earnings before the bell on Tuesday, with market expectations for flat revenue year-over-year, indicating a potential recovery from the 7.8% decline recorded in the same quarter last year.
- Revenue Performance: Last quarter, Pfizer reported revenues of $17.56 billion, down 1.2% year-over-year, which, while beating analyst expectations, showed a significant miss on organic revenue estimates, highlighting ongoing challenges for the company.
- Market Sentiment: Over the past month, Pfizer's stock has declined by 5.2%, contrasting sharply with peers like Eli Lilly and Merck, which reported revenue growth of 55.5% and 4.9%, respectively, indicating Pfizer's competitive disadvantages.
- Analyst Expectations: With an average analyst price target of $29.00 against a current share price of $26.38, there is a cautious outlook on Pfizer's future performance, especially as most analysts have revised their revenue estimates downward.
See More
NASDAQ 100 Pre-Market Indicator Rises Significantly
- Market Indicator Surge: The NASDAQ 100 Pre-Market Indicator rises by 205.3 points to 27,857.12, indicating a positive shift in market sentiment that may attract more investor interest in tech stocks.
- Active Stock Performance: GraniteShares 2x Long COIN Daily ETF (CONL) increases by 0.7 to $9.72 with a trading volume of 5,185,460 shares, representing a 93.63% rise from its 52-week low, reflecting sustained investor interest in cryptocurrencies.
- Intel Earnings Forecast Revisions: Intel Corporation (INTC) sees its stock price rise by 3.73 to $99.51 with 4,203,982 shares traded, as it has had 10 upward revisions in earnings forecasts over the past four weeks, showcasing market confidence in its future financial performance.
- Circle Internet Earnings Report Preview: Circle Internet Group, Inc. (CRCL) shares rise by 5.55 to $125.08 with a trading volume of 2,278,329 shares, scheduled to report earnings on May 11, 2026, with a consensus EPS forecast indicating a staggering 99,900% increase, highlighting strong growth potential.
See More
PayPal and Anheuser-Busch Beat Earnings Expectations
- PayPal Earnings Surprise: PayPal reported first-quarter earnings of $1.34 per share, exceeding analyst expectations of $1.27, with revenues of $8.35 billion surpassing the $8.05 billion forecast, indicating strong performance in the payments sector that could drive stock price increases.
- Anheuser-Busch Strong Growth: Anheuser-Busch reported earnings of $0.97 per share, beating the expected $0.89, with revenues of $15.27 billion significantly above the $14.87 billion forecast, demonstrating sustained competitiveness in the beer market that may attract more investor interest.
- Pfizer Exceeds Expectations: Pfizer's first-quarter earnings came in at $0.75 per share, above the $0.72 expected, with revenues of $14.45 billion, reflecting robust growth in the pharmaceutical sector that could enhance market confidence in its future products.
- Pinterest Optimistic Revenue Guidance: Pinterest's second-quarter revenue guidance of $1.13 billion to $1.15 billion exceeded the $1.11 billion expected, with first-quarter adjusted earnings of $0.27 per share and revenues of $1.01 billion, showcasing strong growth potential in the social media space that is likely to improve market perceptions of its long-term value.
See More
Pfizer Q1 Earnings Exceed Expectations
- Strong Performance: Pfizer reported adjusted earnings per share of 75 cents for Q1, surpassing the expected 72 cents, with revenue of $14.45 billion reflecting a 5% year-over-year increase, demonstrating robust market performance driven by both new and established products.
- Growth in New Products: The company saw a 22% operational growth in recently launched and acquired products, with the targeted cancer drug Padcev generating $591 million in revenue, a 39% increase from the previous year, exceeding analyst expectations of $542.3 million, indicating a strong return on investment in innovative therapies.
- Decline in Vaccine Sales: Despite the Covid vaccine and Paxlovid generating only $232 million and $186 million in sales, down 59% and 62% year-over-year respectively, Pfizer offset this impact with strong performance from established drugs like Eliquis, which generated $2.17 billion, a 13% increase.
- Stable Long-term Outlook: Pfizer reaffirmed its 2026 outlook, expecting adjusted earnings per share between $2.80 and $3.00 and revenue between $59.5 billion and $62.5 billion, reflecting confidence in navigating challenges from declining Covid product sales and increased market competition.
See More
Pfizer Reports Strong Q1 Earnings, Reaffirms 2026 Outlook
- Earnings Beat: Pfizer's adjusted earnings per share for Q1 reached 75 cents, exceeding the expected 72 cents, reflecting strong performance in newly launched and acquired products, which bolsters investor confidence.
- Revenue Growth: The company reported Q1 revenue of $14.45 billion, surpassing Wall Street's expectation of $13.79 billion, indicating significant growth in its new product offerings and acquisitions, further solidifying its market position.
- Strategic Acquisition: Pfizer's recent $10 billion acquisition of obesity biotech Metsera aims to diversify its product line to offset declining COVID product sales, demonstrating the company's strategic focus on future growth.
- R&D Focus: Pfizer is prioritizing several key data releases this year, including late-stage trial results for an experimental targeted drug in lung cancer, which is expected to drive new growth opportunities for its product pipeline.
See More
BioNTech to Close Sites Affecting 1,860 Jobs and Buy Back $1 Billion in Shares
- Job Cuts and Site Closures: BioNTech announced the closure of multiple sites in Idar-Oberstein, Marburg, and Tuebingen in Germany, as well as in Singapore, affecting up to 1,860 jobs, reflecting a strategic shift following the transfer of COVID-19 vaccine production to partner Pfizer.
- Executive Departures Impact: The departure of the two co-founders and key executives by year-end to focus on new treatments may impact the company's innovation capacity and market competitiveness, particularly in the vaccine sector.
- Cost-Cutting Initiatives: BioNTech plans to implement gradual cost reductions, potentially achieving annual savings of about €500 million by 2029, aimed at improving financial health amid reported net losses.
- Share Buyback Program: The company announced a share buyback of up to $1 billion over the next 12 months to bolster shareholder confidence and enhance stock prices, despite reporting a net loss of €532 million in the first quarter, indicating current financial pressures.
See More
